The A1 allele of the dopamine D2 receptor gene (DRD2) is associated with a reduced number of dopamine binding sites in the brain and with the increased likelihood of substance abuse and addictive behavior. In a study of smokers enrolled in an open-label, randomized effectiveness trial, we investigated whether variants in the DRD2 receptor gene are associated with smoking cessation outcomes following treatment with a combination of bupropion SR and behavioral counseling. Adherence to treatment and pointprevalent smoking status were assessed at 3 and 12 months, respectively, following a target quit date. Compared to women who carry both A2 alleles, women with at least one A1 allele were more likely to report having stopped taking bupropion due to medication side effects (odds ratio (OR) ¼ 1.91, 95% confidence interval (CI) ¼ 1.01-3.60; Po0.04) and at 12 months were somewhat more likely to report smoking (OR ¼ 0.76, 95% CI ¼ 0.56-1.03; Po0.076). Significant associations or trends were not observed in men. In women, individual variability in responsiveness to bupropion-based treatment may be partially due to differences in genetic variants influencing dopamine receptor function. 
INTRODUCTION
Tobacco use remains the major preventable cause of premature disability and death in developed countries. Despite best efforts to date, 46 million people still smoke in the United States, and over 440 000 people die each year from tobaccorelated illness; the estimated smoking-related cost to the economy is $157 billion annually. 1 Effective pharmacologic interventions for smoking cessation include several forms of nicotine replacement and the use of the antidepressant medication, bupropion. 2 Despite treatment advances, smoking relapse after successful intervention for smoking cessation occurs in 70 to 80% of patients within 12 months. [3] [4] [5] Still to be determined is why some people remain nonsmokers after pharmacologic intervention and others do not.
The dopaminergic mesocorticolimbic pathway in the brain is thought to play an important role in tobacco and nicotine addiction. [6] [7] [8] The TaqIA polymorphism of the dopamine D2 receptor gene (DRD2) results from a C/T single-nucleotide polymorphism (SNP) located at 10 541 bp downstream of the termination codon and in the 3 0 -flanking region of DRD2. 9 This polymorphism is located within the ankyrin repeat and kinase domain containing 1 gene (ANKK1), a previously uncharacterized gene immediately adjacent to the DRD2 gene. Although residing outside the DRD2 gene, the TaqIA polymorphism could be in linkage disequilibrium with other functional polymorphisms within the DRD2 gene. The A1 allele of DRD2 has been shown to be associated with a reduced number of dopamine binding sites in the brain [10] [11] [12] and is hypothesized to play a role in nicotine addiction by causing a hypodopaminergic state that is alleviated by chronic exposure to nicotine and other substances of abuse. 13 Clinical studies examining the cross-sectional association between smoking behaviors and the DRD2 TaqIA polymorphism have reported mixed findings. For example, while the DRD2*A1 allele is associated with heavy smoking, 14, 15 current smoking, 15 shorter time of remaining abstinent from cigarettes, 14 and earlier age of onset of cigarette smoking, 14, 15 other studies have failed to show associations between TaqIA polymorphism and ever smoking, smoking amount, or nicotine dependence. [16] [17] [18] A recent meta-analysis of the literature concluded that, after accounting for between-study heterogeneity, the effect of DRD2 on all measures of smoking status was no longer statistically significant. 19 The dopaminergic reward pathway has also been a target of pharmacological treatment for smoking cessation. Indeed, the effects of bupropion sustained-release (SR), the only approved non-nicotinic medication, are thought to be mediated by dopaminergic mechanisms such as by blocking the reuptake of dopamine. [20] [21] [22] [23] While several placebocontrolled trials of bupropion SR for smoking cessation have demonstrated its efficacy to promote smoking cessation 21, 24, 25 and a recent field trial has also shown the effectiveness of bupropion in actual practice, 26, 27 only a minority of smokers treated with bupropion SR quit smoking for clinically meaningful periods (approximately 25-30% at 1 year follow-up).
The extent to which genetic variants in the dopamine reward system influence individual response to treatment with bupropion has only recently been explored. Two studies have examined the DRD2 genotype in relation to various outcomes following treatment for smoking cessation. 28 , 29 David et al 28 reported that bupropion significantly attenuates specific symptoms of the nicotine withdrawal syndrome only among subjects with DRD2-TaqI A2/A2 genotype. In a placebo-controlled clinical trial, however, Lerman et al 29 reported that the DRD2 genotype alone was not significantly associated with treatment outcome. Owing to the small number of previous studies, additional clinical studies are needed to confirm these associations.
Another factor that could affect treatment outcome with bupropion SR is gender. Gender differences have been reported in the effectiveness of bupropion treatment. Specifically, women experience higher rates of smoking following treatment with bupropion SR than do men, 30, 31 and there is substantial heterogeneity in 12-month smoking rates within women, ranging from a low of 57.1% to a high of 90.2% across six identified subgroups. 32 Since DRD2 receptor affinity is lower in women than in men, it is possible that DRD2-mediated mechanisms underlie heterogeneity of treatment response, 33 a possibility that was not addressed by Lerman et al 29 or by David et al.
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In the following pharmacogenetic study, we investigated the effect of DRD2 genotype on smoking cessation outcome following 8 weeks of treatment with bupropion SR in an open-label, randomized effectiveness study in a large healthcare system. Our first goal was to examine whether individuals carrying at least one DRD2-TaqIA1 allele would be more likely to remain smokers at the 12-month follow-up after treatment with bupropion SR. As more information is needed on potential gender differences in responsiveness to treatment for smoking cessation, 34, 35 the second goal of this study was to examine whether the relationship between DRD2 polymorphism and smoking outcomes varied as a function of gender. .005) compared to men. Women and men were similar with respect to body mass index, nicotine dependence, number of previous quit attempts, likelihood of having a previous quit attempt greater than 6 months in length, of having quit for at least 24 h in the year prior to enrollment in the study, and indicators of adherence to the therapeutic regimen.
RESULTS

Comparability of Participants and
Genotype Differences in Pretreatment Measures of Tobacco
Dependence, Adherence to Treatment, and Smoking Cessation Treatment Outcome Given the low frequency of the A1A1 homozygote (n ¼ 19) and consistent with the genotype groupings in previous studies, 28, 29 DRD2 genotype was classified as the presence or absence of the A1 allele (A1A1 or A1/A2 vs A2/A2) and a dominant genetic model was assumed. Pretreatment and treatment characteristics of the 416 Caucasian participants are shown in Table 2 for the two DRD2 genotype subgroups (A1 þ and A2A2).
No significant association was observed between DRD2 genotype, intensity of behavioral counseling, and any of the pretreatment characteristics, including the amount smoked at baseline, level of nicotine dependence as measured by the Fagerström Test for Nicotine Dependence (FTND), and the number or length of past quit attempts. However, a trend was observed in the association between DRD2 genotype and adherence. Specifically, the A1 þ carriers were somewhat more likely to report having stopped taking medication due to side effects than were those with the A2A2 genotype (31.4 vs 22.6%; Po0.096).
Variation in Genotype-Phenotype Associations as a Function of Gender
The analyses reported in Table 2 were repeated separately for female and male participants. Again, no significant association was observed between DRD2 genotype, intensity of behavioral counseling, and the pretreatment characteristics among either female or male participants.
For treatment adherence, DRD2 status was associated with the likelihood of stopping bupropion SR because of side effects among female participants ( Figure 1 ). The odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) were computed by logistic regression with dose (150 or 300 mg) and age as covariates, and can be interpreted as the odds of stopping treatment due to side effects as a function of the presence of the A1 allele. The odds among female carriers of the A1 allele of stopping bupropion SR were almost twice as high as for female noncarriers (OR ¼ 1.91, 95% CI ¼ 1.01-3.60, Po0.04), whereas this association was not observed in men (OR ¼ 1.09, 95% CI ¼ 0.58-2.05, Po0.96).
Using 12-month point-prevalent nonsmoking as the outcome, ORs, CIs, and significance levels were computed by logistic regression with age and dose (150 or 300 mg) as covariates. We observed a trend such that women carrying at least one A1 allele were somewhat less likely to quit smoking (OR ¼ 0.76, 95% CI ¼ 0.56, 1.03; Po0.076; Table 3 ).
Furthermore, a significant association between the number of A1 allele copies carried by female smokers (A1A1, A1A2, vs A2A2) and 12-month nonsmoking was observed. Specifically, the percentage of 7-day point prevalence of nonsmoking at 12 months among the three genotype groups in female participants was 17.5714% (A1A1), Figure 2 ). This trend was not observed in men. Logistic regression analyses were also conducted to test for an interaction between genotype and gender. The two-way interactions between genotype and gender on the likelihood of stopping medication due to side effects (Po0.14) and likelihood of being a nonsmoker at the 12-month follow-up (Po0.12), while suggestive, were not statistically significant.
DISCUSSION
In the present study, we investigated the relationship between the TaqIA polymorphism at the DRD2 receptor gene and clinically relevant adherence and smoking end points following treatment with bupropion SR in a large health-care system. This is the first large-scale pharmacogenetic study conducted outside of a clinical efficacy trial. Unlike a clinical efficacy trial where in-person screening and treatment occur at a high level, the setting in the present study is a more realistic representation of what is provided in a typical health-care system.
The overall lack of association between DRD2 genotype and various smoking-related phenotypes is consistent with several previous studies and the conclusions of the metaanalysis conducted by Munafò et al. 19 The main effect of DRD2 on indices of tobacco dependence, by itself, is modest at best, and the present study lends further support to this conclusion.
Modest variation as a function of gender in genotypeoutcome associations was observed in the present study. Compared to women who carry both A2 alleles, women Odds ratios and significance levels were computed by logistic regression with age and dose (150 or 300 mg) as covariates (and gender for women and men combined). b The percentages shown are the least-squares mean adjusted for age and dose7standard error.
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with at least one A1 allele were more likely to report having stopped taking bupropion SR due to adverse effects. There was also a trend for these women to be more likely to report smoking at the 12-month follow-up. Similar trends were not observed in men. Thus, it appears that the presence of the A1 allele may differentially place women at higher risk for smoking relapse following treatment with bupropion. It is possible that women with at least one A1 allele are less able to tolerate the adverse effects of bupropion and are thus more likely to be nonadherent to the bupropion regimen. One possible explanation for the nonadherence due to adverse effects of A1 þ women to the bupropion SR regimen could stem from gender differences observed in the metabolism of bupropion SR. Stewart et al 39 reported that adolescent girls tend to have slower rates of metabolism following a single dose of bupropion (eg longer half-life, larger maximum plasma concentration) than similarly aged boys. However, gender differences in pharmacokinetics of bupropion and its metabolites were not evident in an adult sample. 40 Further research is needed to clarify if there are any gender differences in the metabolism of bupropion SR as used in a real-world setting.
Studies have also examined whether there are hormonal influences on the expression of hepatic CYP2B6 enzyme, the primary P450 gene involved in the metabolism of bupropion 41, 42 and on the pharmacokinetics of bupropion. Palovaara et al 43 reported that hormone replacement therapy (HRT) markedly inhibited the CYP2B6-catalyzed hydroxylation of bupropion, whereas a combination oral contraceptive had only a modest effect on CYP2B6 activity, suggesting that patients receiving HRT or oral contraceptives may need dose adjustment when treated with drugs metabolized by CYP2B6. Variations in estrogen level and their impact on CYP2B6 activity could explain women's variable response to bupropion in this trial.
In addition, the adverse effect profile of bupropion SR was more pronounced in women than in men. The gender effects on the dopaminergic pathways in the brain could be via direct or indirect mechanisms. Preclinical studies have shown that female animals exhibit greater sensitivity to dopaminergic agonists than males. 44 In addition, unique to females, there is evidence at the animal level that dopaminergic transmission varies with the estrous cycle phase. 45, 46 Clinical studies have shown that DRD2 receptor affinity is lower in women than in men, 33 and that women show greater dopamine transporter availability than men. 47, 48 It is possible that sex hormones could affect neurotransmission in brain regions that are important in nicotine addiction and relapse. Specifically, the expression of the A1 þ allele in women with lower estrogen levels could result in an especially high-risk convergence of risk factors for relapse. Since estrogen levels and genetic polymorphisms in sex hormone biosynthesis and metabolism pathways were not measured in the present investigation, future studies will be needed to examine whether an interaction between the endocrine and central nervous systems can alter responses to pharmacologic treatments for smoking cessation.
To date, two pharmacogenetic studies of individual genotype associated with smoking cessation outcome following treatment with bupropion SR have been published. 29, 49 While Lerman et al 29 reported no influence of the DRD2 genetic polymorphism, by itself, on the smoking cessation rate at either the end of treatment or at 6 months, individuals homozygous for the DRD2 A2 allele and for the 10-repeat allele of the dopamine transporter gene, DAT1, were significantly more likely to be abstinent at the end of treatment (although not at 6-month follow-up), suggesting the presence of a gene-gene interaction. While gender differences in smoking treatment outcomes were evident in this study, the influence of gender on the molecular association was not reported. Lerman et al 49 have further shown that variation in CYP2B6 is also related to smoking outcomes following treatment with bupropion SR and that this association may be mediated by gender. The presence of a gene-gene interaction was not examined in this report.
Sample size is a major issue for pharmacogenetic study design. DRD2 and CYP2B6 are but two of the many candidate genes implicated in the relevant biological pathways directly involved in the 'reward deficit syndrome' (see, for example, Walton et al 50 ) and bupropion response. Therapeutic response is likely to be the result of the interaction between several metabolic and receptor genes. 51 Cardon et al 52 evaluated clinical trial sampling requirements under different allele frequencies, gene action, gene effect size, and number of markers in a genome screen. The allele frequency and type of gene action can have a dramatic impact on trial sample sizes. In many cases, the necessary sample size for a pharmacogenetic investigation of modest genetic effects and of gene-gene interaction will be quite large (eg 45000). Thus, it is quite probable that the present and previous studies 28, 29, 49 were substantially underpowered to facilitate the necessary analyses of multiple genotypes. Larger clinical trials are, therefore, needed to adequately test both univariate and multivariate genetic hypotheses as they pertain to clinically relevant treatment outcomes. 
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One limitation with the use of an open-label study design as in this trial is the lack of blinding, a consequence of conducting this work within the context of a large healthcare system where ethical and practical concerns are of highest priority. As this study was conducted in an actual practice setting, it relied entirely upon telephone and mailed interaction between study participants and project staff. Therefore, several methodological refinements usually found in clinical trials of drug efficacy, including the use of placebo medication, biochemical confirmation of nonsmoking, and confirmation of medication adherence, were not logistically feasible and could potentially represent important limitations in our study. Previous analyses suggest that the rate of under-reporting of smoking in a field trial of this type may be minimal. [53] [54] [55] [56] The present study provides modest evidence that genotypic variation is related to women's responsiveness to treatment with bupropion for smoking cessation in a realworld setting. Collectively, the results from the present study, along with those from the three previous pharmacogenetic studies on bupropion SR, 28, 29, 49 provide modest support for the hypothesis that genetic variation plays a role at key points along the therapeutic pathway (eg adherence, abstinence effects, adverse effects, and clinical end points) in response to pharmacological treatment for smoking cessation.
While adherence to any type of medication regimen is critical to maximizing positive therapeutic outcome, very little is known about adherence to bupropion SR either in the context of treatment for depression or for smoking cessation, a gap in the literature that is surprising given its side effect profile. 21 Recent work in the field of depression identifies adverse medication effects as among the reasons for nonadherence. [57] [58] [59] [60] Although several studies have reported adherence to SSRIs for the treatment of depression, 61, 62 none have evaluated adherence to bupropion SR, and a recent meta-analysis of the smoking cessation pharmacotherapy literature did not address the issue. 63 A better understanding of the predictors, including genotype, of nonadherence to bupropion therapy is needed. The fact that, in the present study, female carriers of the A1 allele were more likely to stop taking bupropion due to side effects suggests that efforts to better understand the biological contributors to nonadherence should begin with these individuals. This information could be used, in turn, to facilitate development of more effective treatments for smoking cessation that are tailored to individual genetic profiles.
MATERIALS AND METHODS
Study Participants and Trial Design
This open-label, randomized effectiveness study of smoking cessation treatment was performed at Group Health Cooperative (GHC), a large health-care system based in Seattle, WA, USA. A complete description of study methodology is available elsewhere. 26, 27 Briefly, a total of 1524 participants were assigned randomly to receive one of four combinations of bupropion and counseling: 150 mg bupropion SR with less intensive counseling (n ¼ 382) or with more intensive counseling (n ¼ 381); or 300 mg bupropion SR with less intensive counseling (n ¼ 383) or more intensive counseling (n ¼ 378). Less intensive counseling consisted primarily of tailored mailings, and more intensive counseling consisted primarily of a series of five proactive phone calls. Participants were mailed an 8-week prescription of bupropion SR prior to their target quit date, and then were assessed at 3 months after the target quit date for adherence to the regimen, abstinence, and side effects, and again at 12 months to determine smoking status.
Participants who responded to the 12-month follow-up (n ¼ 1299) were invited to participate in the 'genetic factors' supplemental study. The timing of the solicitation for volunteers (eg at the end of follow-up rather than at the beginning of the study) was necessary for three reasons: (1) the availability of supplemental support from the funding agency to support data collection and genotyping efforts; (2) the need for a second review by the Institutional Review Boards of GHC and SRI International; and (3) the need to reconsent participants after approval to proceed with the genotyping component of the study was received by the investigators. A total of 993 12-month responders (78%) agreed to be sent materials to collect buccal cell samples (four sterile cotton swabs, sealable plastic bag, detailed instructions for sample collection, and postage paid return envelope), and of this number, a total of 496 (50%) actually provided samples.
Measures
The pretreatment questionnaire consisted of: (a) smoking history including the FTND 64 ; (b) quitting history and prior use of cessation aids; and (c) demographics including date of birth, ethnicity, and education.
At the 3-month follow-up, participants were asked whether or not they experienced any of a series of adverse or abstinence effects since taking bupropion SR. Adverse effects included: difficulty sleeping, shakiness/tremor, dizziness, dry mouth, rhinitis, rash, nausea, and gastrointestinal problems. Abstinence effects included: desire to smoke, difficulty concentrating, irritability/anger, depression, confusion, tension/agitation, anxiety, increased or decreased appetite, blood pressure changes, or racing thoughts. A total score was created for each set of symptoms based on the number checked affirmatively. Self-reported adherence to the medication regimen was also assessed at the 3-month follow-up. Participants were asked to report whether they stopped taking bupropion SR because of side effects (yes/no). At the 12-month follow-up, participants' smoking pattern within the preceding 7 days was assessed. Any smoking within that interval was defined as point-prevalent smoking according to recently published conventions described elsewhere. 65 
Buccal Cell Collection Procedures
The method used to collect buccal cells was a modified version of the protocol detailed in Freeman et al. 66 Participants were provided instructions for collecting buccal cell samples, and were requested to avoid collection within an hour of brushing teeth or if there were bits of food in the mouth. Participants were instructed to rub the inside of their mouths with a sterile cotton swab, and to rub each of four swabs in such a way that all sides of the cotton touched the mouth for at least 20 s. Once all four cotton swabs had been used, the participants were asked to seal them tightly in the plastic bag and return them by mail as soon as possible. Upon receipt, the swabs were frozen and then sent in batches to the laboratory for DNA extraction.
Genomic DNA Preparation and Genotyping Method Genomic DNA was extracted from the buccal swabs by a standard NaOH/heat cell lysis protocol. Specifically, the buccal swabs were immersed into a 1.5 ml tube with 540 ml of lysis buffer containing 0.01 Â Triton, lightly vortexed, and spun at 20 200 RCFg for 1 min to dislodge the cells. A measure of 60 ml 500 mM NaOH was added. The samples were vortexed for 10 s, followed by incubation at 951C for 5 min. The cotton swabs were removed by sterile forceps and the solutions were neutralized by 60 ml 1 M Tris buffer. The DNA samples were stored at 41C until quantitation.
The NCBI reference SNP cluster identifier for the DRD2-TaqIA polymorphism is rs1800497. This polymorphism was originally reported as an RFLP assay, 9,67 but was genotyped in this study using the 5 0 -fluorescence exonuclease (TaqMan) method. 68, 69 The 76 bp amplicon carrying the DRD2 TaqIA locus was amplified by flanking PCR primers: 5 0 -GTG TGC AGC TCA CTC CAT CCT-3 0 (DRD2-TaqIA-F) and 5 0 -GGG CAACAC AGC CAT CCT-3 0 (DRD2-TaqIA-R). The TaqIA SNPs (TGCCT-C/T-GACCA) were detected in an allele discrimination assay using the dual-labeled allele-specific probes: 5 0 -VIC-CGC CTG CCT cGA CCA GCA C-TAMRA-3 0 (DRD2-TaqIAC-VIC, for wild-type C-allele) and 5 0 -6FAM-CGC CTG CCT tGA CCA GCA CTT T-TAMRA-3 0 (DRD2-TaqIAt-FAM). TaqMan reactions were carried out using reagents supplied by the vendor (Applied Biosystems), with 900 nM each of forward and reverse PCR primers and 200 nM each of the FAM-and VIC-labeled TaqMan probes. Approximately 2-20 ng of genomic DNA was used per 15 ml reaction. PCR amplification was carried out for 40 cycles under standard TaqMan conditions (UNG activation: 501C, 2 min; AmpliTaq Gold activation: 951C, 10 min; Denature: 951C, 15 s; Anneal/extend: 601C, 1 min), using the ABI7900 Sequence Detection System in the 384-well format.
Statistical Methods
Statistical analyses were performed using the S-Plus package 2000 release 3 (Insightful Corporation, Seattle, WA, USA). w 2 tests and t-tests were used to evaluate differences between genotype classes in categorical and continuous variables, respectively. When adjusting for covariates, logistic regressions were used for categorical variables and analyses of covariance were used for continuous variables. w 2 analysis was used to test whether the distribution of genotypes was in accordance with Hardy-Weinberg equilibrium.
To examine the association between DRD2 TaqIA genotype and smoking cessation treatment outcome measures, logistic regression models were fitted separately for women and men and included genotype status (A1 þ vs A2A2), age, and bupropion SR dose utilized (150, 300 mg) as covariates. Age, gender, and bupropion dose were included as covariates, as they are potential confounds of the association between genotype and treatment outcomes. Given the low frequency of the A1A1 homozygote, for most traits, a dominant genetic model (A1 þ vs A2A2) was considered. However, for treatment outcomes where a clear linear trend was observed, an additive genetic model (A1A1, A1A2 and A2A2) was also tested.
